Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
17.61M
Cash
40.78M
Avg Qtr Burn
-7.976M
Short % of Float
4.70%
Insider Ownership
13.52%
Institutional Own.
23.57%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EryDex Details Rare genetic disease, Neurological disorder, Ataxia Telangiectasia | Phase 3 Data readout | |
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Alzheimer's disease, Neurological disorder | Failed Discontinued | |
COR588 (Lysine gingipain inhibitor) Details Mental health, Alzheimer's disease, Neurological disorder | Failed Discontinued | |
Atuzaginstat (COR388) (Lysine gingipain inhibitor) Details Periodontal disease | Failed Discontinued | |
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Parkinson's disease | Failed Discontinued |